Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | CASP1 | P29466 | 1/20 | 0.61 |
| ▸ | CASP7 | P55210 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979684 | 0.81 | KDM4E (0.69) | KDM4EALDH1A1MAPK1LMNAHPGD | |
| SCHEMBL980624 | 0.81 | KDM4E (0.77) | KDM4EALDH1A1MAPK1LMNAHPGD | |
| SCHEMBL5545639 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1MAPK1LMNAHPGD | |
| SCHEMBL981898 | 0.80 | KDM4E (1.00) | KDM4EALDH1A1MAPK1LMNAHPGD | |
| SCHEMBL230441 | 0.79 | HTT (0.62) | KDM4EALDH1A1MAPK1LMNAHPGD | |
| SCHEMBL31300308 | 0.78 | KDM4E (0.63) | KDM4EALDH1A1MAPK1LMNAHPGD | |
| Ataquimast SCHEMBL1150373 | 0.78 | KDM4E (0.65) | KDM4EALDH1A1MAPK1LMNAHPGD | |
| Ataquimast SCHEMBL29388447 | 0.78 | KDM4E (0.65) | KDM4EALDH1A1MAPK1LMNAHPGD | |
| SCHEMBL982499 | 0.76 | MAPK1 (0.75) | KDM4EALDH1A1MAPK1LMNAHPGD | |
| SCHEMBL980794 | 0.75 | ALDH1A1 (0.73) | KDM4EALDH1A1MAPK1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247580-B1 | QUINOXALINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2015-07-08 | — | — | EP | disclosed |
| US-8835634-B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-8835634-B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-8835634-B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| CN-101952258-B | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and their use in the treatment of diabetes | MERCK PATENT GMBH | 2014-03-19 | — | — | CN | disclosed |
| US-20130123257-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130123257-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130123257-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-8415352-B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-04-09 | — | — | US | disclosed |
| US-8415352-B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-04-09 | — | — | US | disclosed |
| US-8415352-B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-04-09 | — | — | US | disclosed |
| US-20110015194-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015194-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015194-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-2247580-A1 | QUINOXALINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009109258-A1 | QUINOXALINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109258-A1 | QUINOXALINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123257-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | GPR119, IAPP, GLP1R | KDM4E 3341/4885ALDH1A1 2371/4885MAPK1 926/4885 |
| US-20110015194-A1 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | GPR119, IAPP, GLP1R | KDM4E 3341/4885ALDH1A1 2371/4885MAPK1 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.